Get the Stockscreener App
84.81
0.00%
0.00
After Hours:
85.17
0.36
+0.42%
Genedx Holdings Corp stock is traded at $84.81, with a volume of 341.94K.
It is up +0.00% in the last 24 hours and up +30.26% over the past month.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
See More
Previous Close:
$84.81
Open:
$83.84
24h Volume:
341.94K
Relative Volume:
0.36
Market Cap:
$2.53B
Revenue:
$442.68M
Net Income/Loss:
$-77.81M
P/E Ratio:
-31.78
EPS:
-2.6684
Net Cash Flow:
$-28.65M
1W Performance:
-2.97%
1M Performance:
+30.26%
6M Performance:
+6.40%
1Y Performance:
-34.50%
1-Day Range:
$82.79
$85.75
1-Week Range:
$81.19
$91.78
52-Week Range:
$32.21
$170.87
Genedx Holdings Corp Stock (WGS) Company Profile
Name
Genedx Holdings Corp
Sector
Industry
Phone
888-729-1206
Address
333 LUDLOW STREET, STAMFORD
Compare WGS vs TMO, DHR, NTRA, IDXX, IQV
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WGS
Genedx Holdings Corp
|
84.81 | 2.46B | 442.68M | -77.81M | -28.65M | -2.6684 |
TMO
Thermo Fisher Scientific Inc
|
600.50 | 232.03B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
206.93 | 151.78B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
320.76 | 46.82B | 2.50B | -226.32M | 71.51M | -1.6412 |
IDXX
Idexx Laboratories Inc
|
545.16 | 43.00B | 4.45B | 1.10B | 1.06B | 13.59 |
IQV
Iqvia Holdings Inc
|
258.35 | 42.15B | 16.63B | 1.39B | 2.12B | 8.0674 |
Genedx Holdings Corp Stock (WGS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-26 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-20-25 | Initiated | Canaccord Genuity | Buy |
| Jul-09-25 | Initiated | Piper Sandler | Overweight |
| May-15-25 | Initiated | Guggenheim | Buy |
| May-09-25 | Upgrade | Jefferies | Hold → Buy |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jul-10-24 | Initiated | Craig Hallum | Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
View All
Genedx Holdings Corp Stock (WGS) Latest News
A Look at GeneDx Holdings Corp (WGS) After 5.5% Gain -- GF Value $73.66 vs Price $87.06 - GuruFocus
GeneDx Holdings Corp. $WGS Shares Purchased by Bank of America Corp DE - MarketBeat
Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates? - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages GeneDx Holdings Cor - The National Law Review
Is GeneDx’s Direct-to-Family Exome Platform Reshaping The Investment Case For GeneDx Holdings (WGS)? - Sahm
GeneDx Holdings Corp. (WGS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-08-18 | GeneDx Holdings Corp. (WGS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:WGS | Press Release - Stockhouse
GeneDx: Why I Think The Worst Is Behind The Business (NASDAQ:WGS) - Seeking Alpha
WGS DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Inv - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating GeneDx Holdings Corp. (WGS) And Encourages Investors to Connect - ACCESS Newswire
WGS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announce - The National Law Review
GeneDx Holdings (WGS) Slips 1.35% to $78.08, Holds Midpoint of Trading RangeCall Flow Alert - Vinanet
GeneDx Holdings (WGS) Slips 1.35% as Shares Hold Between Key Support and ResistanceDelta Hedging - Vinanet
GeneDx Holdings (WGS), Why Is This Fresh Development Drawing Attention? - Sahm
Precision Trading with Genedx Holdings Corp. (WGS) Risk Zones - Stock Traders Daily
The Manufacturers Life Insurance Company Sells 12,820 Shares of GeneDx Holdings Corp. $WGS - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating GeneDx Holdings Corp. (WGS) And Encourages Stockholders to Connect - ACCESS Newswire
Sei Investments Co. Trims Stock Position in GeneDx Holdings Corp. $WGS - MarketBeat
Is GeneDx Holdings Corp (WGS) Overvalued After 5.1% Rally? GF Va - GuruFocus
GeneDx Holdings Corp. (WGS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Goldman Sachs Group (WGS) discloses 5.8% beneficial stake in GeneDx Class A - Stock Titan
GeneDx at Canaccord Genuity conference: volume rises, collections lag - Investing.com
GeneDx Holdings (WGS) Is Up 14.8% After Loss-Making Q2, New Capital Raise And Guidance Reaffirmation - simplywall.st
GeneDx launches online exome testing for pediatric patients - Investing.com
GeneDx Lets Families Start Children’s Exome Testing Online - Stock Titan
GeneDx Holdings Corp. (WGS) Stock Analysis: A Genomics Pioneer with 10.28% Upside Potential - DirectorsTalk Interviews
Assenagon Asset Management S.A. Acquires 208,305 Shares of GeneDx Holdings Corp. $WGS - MarketBeat
GENEDX HOLDINGS CORP. : PIPER SANDLER RAISES TARGET PRICE TO $95 FROM $63 - Moomoo
GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026 - The National Law Review
GeneDx Holdings Corp. $WGS Shares Acquired by Dimensional Fund Advisors LP - MarketBeat
GeneDx (NASDAQ:WGS) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
GeneDx Holdings (WGS) Is Up 18.4% After Reaffirming 2026 Outlook And Raising Equity From Blackstone - Yahoo Finance
WGS CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds GeneDx (WGS - The National Law Review
GeneDx Holdings (WGS): ARK Investment and Cathie Wood report 5.33% ownership - Stock Titan
GeneDx Holdings Corp (WGS) Stock News Today - TradingKey
WGS SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Annou - The National Law Review
GeneDx to Participate in Upcoming Investor Conferences - marketscreener.com
GeneDx Holdings Corp. (NASDAQ:WGS) Analysts Are Pretty Bullish On The Stock After Recent Results - simplywall.st
GeneDx Holdings Corp. Earnings Call Highlights Risks - The Globe and Mail
GeneDx Holdings Corp. (WGS) Options Chain - Yahoo! Finance Canada
Cathie Wood’s ARK sells Palantir stock, buys GeneDx Holdings - Investing.com
Cathie Wood’s ARK sells Palantir stock, buys GeneDx Holdings By Investing.com - Investing.com Nigeria
GeneDx Holdings Corp. Stock 12‑Month Price Target Raised to $85.89, Implies 27% Upside - TradingView
Canaccord Genuity Group Issues Positive Forecast for GeneDx (NASDAQ:WGS) Stock Price - MarketBeat
GeneDx Holdings Corp. Q2 2026 Earnings Call Summary - Yahoo Finance
GeneDx Holdings Corp. (WGS) Stock Analysis: Strong Buy Ratings and 20% Potential Upside - DirectorsTalk Interviews
GeneDx Holdings Corp (WGS) (Q2 2026) Earnings Call Highlights: Record Volume and Early ... By GuruFocus - Investing.com Canada
GeneDx Holdings (WGS) Is Up 9.7% After Beating Q2 Estimates And Reaffirming 2026 OutlookHas The Bull Case Changed? - simplywall.st
GeneDx Q2 Adjusted Earnings Fall, Revenue Rises; Issues Q3 Outlook - Yahoo Finance
GeneDx Holdings Corp. (WGS) Releases Q2 2026 Earnings: Revenue Beats Estimates but Losses Persist - Quiver Quantitative
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026 - Morningstar
Genedx Holdings Corp Stock (WGS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Genedx Holdings Corp Stock (WGS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RUCH JOSHUA | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
3,576 |
0 |
33,299 |
| PFENNIGER RICHARD C JR | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
3,576 |
0 |
45,082 |
| Meister Keith A. | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
3,576 |
0 |
23,705 |
| Leproust Emily M. | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
3,576 |
0 |
24,852 |
| Casdin Eli | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
3,576 |
0 |
24,093 |
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Jun 16 '26 |
Option Exercise |
0.00 |
7,197 |
0 |
43,683 |
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Jun 16 '26 |
Sale |
60.77 |
3,729 |
226,597 |
39,954 |
| Stueland Katherine | CHIEF EXECUTIVE OFFICER |
Jun 16 '26 |
Option Exercise |
0.00 |
18,750 |
0 |
114,873 |
| Stueland Katherine | CHIEF EXECUTIVE OFFICER |
Jun 16 '26 |
Sale |
60.77 |
10,501 |
638,104 |
104,372 |
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Jun 09 '26 |
Option Exercise |
0.00 |
2,462 |
0 |
37,752 |
1.52%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):